Skip to main content
main-content

Cardiovascular disease and diabetes medication

medwireNews editor's pick

Older type 2 diabetes patients may derive greatest liraglutide benefits

Elderly diabetic patient (symbolic image with models)

The LEADER investigators report that treatment with the glucagon-like peptide-1 receptor agonist liraglutide may be of particular benefit in the oldest patients with type 2 diabetes.

Expert opinion editorial

What have I learned from cardiovascular outcome trials?

Medication arranged in a heart shape

Endocrinologist Sanjay Kalra considers the impact that cardiovascular outcome trials have had on the standard of diabetes care and questions what else they might accomplish in the future [read more]

Get more on: Cardiovascular disease | Type 2 diabetes | Expert opinion

medwireNews editor's pick

DECLARE-TIMI 58 supports CV benefits of SGLT2 inhibitor class

New Content Item

The results of the DECLARE-TIMI 58 trial show a broadly positive effect of dapagliflozin on cardiovascular outcomes, especially heart failure, in patients with type 2 diabetes.

medwireNews editor's pick

Type 2 diabetes, polyvascular disease combine to increase cardiovascular risk

Heartbeat

Type 2 diabetes and polyvascular disease are additive risk factors for cardiovascular events in patients with acute coronary syndromes, a secondary analysis of the IMPROVE-IT trial suggests.

medwireNews editor’s pick

Albiglutide reduces cardiovascular risk in patients with type 2 diabetes

Heart and ECG_Fotolia_287046_Subscription_XL

Results of the Harmony Outcomes trial indicate that adding the glucagon-like peptide-1 receptor agonist albiglutide to standard care may reduce cardiovascular risk among patients with type 2 diabetes and existing cardiovascular disease.

medwireNews editor's pick

Neutral cardiovascular safety for lorcaserin in CAMELLIA-TIMI 61

Heartbeat

The weight-loss medication lorcaserin neither increases nor reduces cardiovascular risk, report the CAMELLIA–TIMI 61 investigators.

Journal article

Risk of heart failure hospitalization among users of dipeptidyl peptidase-4 inhibitors compared to glucagon-like peptide-1 receptor agonists

Doctor holding defibrillator (symbolic image with model)

The authors assess the risk of hospitalization due to HF with the use of dipeptidyl peptidase-4 inhibitors compared to glucagon like peptide-1 receptor agonists [read more].
Dawwas GK, Smith SM, Park H. Cardiovasc Diabetol 2018; 17: 102. doi: 10.1186/s12933-018-0746-4

Get more on:  Diabetic complications | Medication | Type 2 diabetes

medwireNews editor's pick

Continuing metformin advisable for patients starting sulfonylurea treatment

Metformin formula

Research shows that starting second-line sulfonylurea treatment is associated with an increased risk for cardiovascular and hypoglycemic events among patients with type 2 diabetes in clinical practice, although the risk is less if they continue using metformin rather than switching completely.

Journal article

The optimal blood pressure target in diabetes mellitus: A quest coming to an end?

Nurse measuring blood pressure (symbolic image with models)

This review presents the evidence from old and recent trials relevant to optimal blood pressure levels in diabetes mellitus, aiming to shed light in this major clinical question [read more].
Papadopoulou E et al. J Hum Hypertens 2018. doi: 10.1038/s41371-018-0079-5

Get more on:  Diabetic complications | Type 2 diabetes

Journal article

Relationship between sleep disturbance and self-care in adults with type 2 diabetes

Man struggling to sleep (symbolic image with model)

The authors examined the relationship between sleep disturbance and self-care in adults with type 2 diabetes, including both subjective and objective sleep assessments and controlling for potential covariates [read more].
Zhu B et al. Acta Diabetol 2018. doi: 10.1007/s00592-018-1181-4

Get more on:  Diabetic complicationsType 2 diabetes

medwireNews

01-08-2019 | Dapagliflozin | News

Observational data hint at additional dapagliflozin benefits

A real-world study based on DECLARE-TIMI 58 inclusion and outcome criteria shows that dapagliflozin not only reduces cardiovascular risk among patients with type 2 diabetes, in line with the original trial results, but may also lower all-cause mortality risk.

12-07-2018 | Liraglutide (T2DM) | News

Liraglutide cardioprotection replicated in real-world data

Registry data from Denmark and Sweden uphold the cardioprotective effects of liraglutide observed in randomized trials, with the strongest effects seen in patients with established cardiovascular disease.

12-05-2018 | Empagliflozin | News

Empagliflozin beneficial for uncontrolled nocturnal hypertension

The addition of empagliflozin reduces nighttime blood pressure in older diabetes patients who have nocturnal hypertension despite medication including angiotensin receptor blockers, show findings from a randomized trial.

Themed collections

06-25-2018 | SGLT2 inhibitors | Themed collection | Collection

Sodium-glucose cotransporter-2 inhibitors in type 2 diabetes

An updated collection of articles focusing on the mechanism of action and clinical use of sodium-glucose cotransporter-2 inhibitors in patients with diabetes.

Journal articles and book chapters

12-13-2018 | GLP-1 agonists | Review | Article

GLP-1RAs in type 2 diabetes: Mechanisms that underlie cardiovascular effects and overview of cardiovascular outcome data

Sposito AC et al. Cardiovasc Diabetol 2018; 17: 157. doi: 10.1186/s12933-018-0800-2

11-08-2018 | Cardiovascular disorders | Review | Article

The evolving role of the cardiologist in the management of type 2 diabetes

Chilton RJ et al. Curr Diab Rep 2018; 18: 144. doi: 10.1007/s11892-018-1114-1

10-26-2018 | PCSK9 inhibitors | Review | Article

Inhibiting PCSK9: Biology beyond LDL control

Stoekenbroek RM et al. Nat Rev Endocrinol 2018. doi: 10.1038/s41574-018-0110-5

10-15-2018 | Statins | Review | Article

Beyond statins: Who and when to prescribe?

Ganda O. Curr Diab Rep 2018; 18: 126. doi: 10.1007/s11892-018-1087-0

10-08-2018 | Dapagliflozin | Article

Impact of dapagliflozin on left ventricular diastolic function of patients with type 2 diabetic mellitus with chronic heart failure

Soga F et al. Cardiovasc Diabetol 2018; 17: 132. doi: 10.1186/s12933-018-0775-z

Guidelines

A convenient single access point, providing diabetes professionals with links to a comprehensive set of clinical practice guidelines from a wide range of relevant organizations.

Slides

Downloadable PowerPoint slide sets containing a variety of high-quality images and illustrations from Springer Nature’s library of published figures.

Practice tips

Practical information, guidance, and helpful resources for diabetes healthcare providers. Comprised of practical approaches, case studies, and more.

Themed collections

Compendia of selected, recently published, free full-text journal and book content from Springer Nature and other publishers on a particular topic within diabetes management, as recommended by our Editorial Board.

Independent Medical Education

Educational programs building upon the most current research and professional practice recommendations, with the aim of enabling more efficient diagnosis, optimizing treatment, and improving patient outcomes.

image credits